corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 16053

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Rockoff JD.
Lilly Moves Closer to Another Deal Over Zyprexa Marketing
The Wall Street Journal Blog 2009 Jul 22
http://blogs.wsj.com/health/2009/07/22/lilly-moves-closer-to-another-deal-over-zyprexa-marketing/


Full text:

Eli Lilly disclosed today that it was in “advanced discussions” with attorneys general from “several” states over their claims that Zyprexa was marketed for unapproved uses. The company also said it took a pretax $105 million charge against its second-quarter earnings for the potential settlement.

Lilly has faced numerous federal and state investigations into Zyprexa’s marketing for off-label uses. The medicine has FDA approval for treating schizophrenia and bipolar disorders. Zyprexa is Lilly’s top-selling product, with $4.7 billion in sales in 2008, 23% of the company’s revenue.

Lilly didn’t give further details on the potential settlement as part of its upbeat earnings announcement. Here’s more from Dow Jones Newswires on Lilly’s quarterly report as well as on results from Pfizer, which were lower but also beat forecasts.

Lilly has already reached a string of deals on its Zyprexa marketing. In January, the company reached a $1.42 billion Zyprexa accord with the Justice Department that included $800 million to settle civil suits, with $362 million going to states. That effort, which was the largest amount paid by a single defendant in DOJ history, was led by the U.S. Attorney in Philadelphia.

In October, Lilly agreed to pay $62 million to 32 states and the District of Columbia that had been investigating consumer-protection claims. In January 2008, it settled with Alaska for $15 million. Before that, it reached agreements to pay a total of $1.2 billion to 31,000 plaintiffs.

Zyprexa update: There are 12 state Zyprexa lawsuits outstanding against Lilly, and the company is in advanced discussions to settle a “subset” of those, a Lilly spokesman said.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909